Home > ECLIPSE trial: skin clearance independent of PsA status at baseline

ECLIPSE trial: skin clearance independent of PsA status at baseline

Presented By
Prof. Kristian Reich
Conference
AAD 2020
Trial
Phase 3, ECLIPSE
Patients with and without psoriatic arthritis (PsA) at baseline have a similar benefit from treatment with secukinumab and guselkumab at 48 weeks, as was demonstrated in a new analysis of the phase 3 ECLIPSE trial [1]. The ECLIPSE trial compared the anti-IL-23 monoclonal antibody guselkumab head-to-head with the IL-17A blocker secukinumab for the treatment of moderate-to-severe plaque psoriasis. The primary endpoint of the ECLIPSE trial was the proportion of patients achieving a Psoriasis Area and Severity Index (PASI) 90 at week 48. In the overall study population, a significantly greater proportion of patients in the guselkumab group achieved this primary endpoint compared with the secukinumab group. This result was published earlier this year [2]. In the current analysis, proportions of patients at week 48 achieving PASI 90, PASI 100, Investigator’s G...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on